Introduction to ECHO and Biomarker Testing Guidelines Overview

This session provided an overview of the ECHO model, along with providing a data level-set of the current burden of lung cancer in each state, and provide a brief introduction to lung cancer biomarker testing, including the current guidelines and approved FDA biomarker-driven treatments.

Understanding the Barriers and Pathways to Lung Cancer Biomarker Testing Central Hub

This session will provide an overview of the biomarker continuum through the lens of the critical medical stakeholders, showcasing the coordinated sequence of events that is required and the common gaps at every stage of the multidisciplinary care continuum.

Understanding the Barriers and Pathways to Lung Cancer Biomarker Testing Eastern Hub

This session will provide an overview of the biomarker continuum through the lens of the critical medical stakeholders, showcasing the coordinated sequence of events that is required and the common gaps at every stage of the multidisciplinary care continuum.

Adequate Tissue for Sampling Central Hub

This session will define the overall role of the multidisciplinary care team, including the coordination by pathologists and medical oncologists to ensure adequate lung cancer tissue is collected for testing. Additionally, it will provide guidance on how to procure adequate tissue samples that allow for accurate characterization of histology, biomarker testing, and the tissue and discuss the approaches of the different proceduralists.

Adequate Tissue for Sampling Eastern Hub

This session will define the overall role of the multidisciplinary care team, including the coordination by pathologists and medical oncologists to ensure adequate lung cancer tissue is collected for testing. Additionally, it will provide guidance on how to procure adequate tissue samples that allow for accurate characterization of histology, biomarker testing, and the tissue and discuss the approaches of the different proceduralists.

Choice of Panel, Interpretation of Results, and Next Steps - Central Hub

This session will provide guidance and recommendations regarding the appropriate biomarker testing modalities (next-generation sequencing (NGS), Fluorescence in situ hybridization (FISH), and blood. Additionally, it will discuss how to interpret the current NGS reports and the appropriate next steps, e.g. recommendations for FDA approved treatments or cancer clinical trials (if no FDA approved treatment exists, etc.).

Choice of Panel, Interpretation of Results, and Next Steps – Eastern Hub

This session will provide guidance and recommendations regarding the appropriate biomarker testing modalities (next-generation sequencing (NGS), Fluorescence in situ hybridization (FISH), and blood. Additionally, it will discuss how to interpret the current NGS reports and the appropriate next steps, e.g. recommendations for FDA approved treatments or cancer clinical trials (if no FDA approved treatment exists, etc.).

Improving Turnaround Time – Central Hub

This session will offer strategies to reduce turnaround time and present approaches to help ameliorate the patient’s wait time for the results.

Improving Turnaround Time - Eastern Hub

This session will offer strategies to reduce turnaround time and present approaches to help ameliorate the patient’s wait time for the results.

Texas - Biomarker Testing, Precision Medicine and Insurance Complexities

This session will explore the current coverage policies and reimbursement for single gene tests, as compared to multi-gene panel tests by private and public payers in each state and provide solutions to overcome reimbursement barriers.

Arkansas- Navigating Insurance Complexities

This session will explore the current coverage policies and reimbursement for single gene tests, as compared to multi-gene panel tests by private and public payers in each state and provide solutions to overcome reimbursement barriers.

Louisiana - Navigating Insurance Complexities

This session will explore the current coverage policies and reimbursement for single gene tests, as compared to multi-gene panel tests by private and public payers in each state and provide solutions to overcome reimbursement barriers.

Tennessee - 2023 and Beyond

This session will explore the current coverage policies and reimbursement for single gene tests, as compared to multi-gene panel tests by private and public payers in each state and provide solutions to overcome reimbursement barriers.

West Virginia - Navigating Insurance Complexities

This session will explore the current coverage policies and reimbursement for single gene tests, as compared to multi-gene panel tests by private and public payers in each state and provide solutions to overcome reimbursement barriers.

Florida - Navigating Insurance Complexities

This session will explore the current coverage policies and reimbursement for single gene tests, as compared to multi-gene panel tests by private and public payers in each state and provide solutions to overcome reimbursement barriers.

Virginia - Navigating Insurance Complexities

This session will explore the current coverage policies and reimbursement for single gene tests, as compared to multi-gene panel tests by private and public payers in each state and provide solutions to overcome reimbursement barriers.

South Carolina - Navigating Insurance Complexities

This session will explore the current coverage policies and reimbursement for single gene tests, as compared to multi-gene panel tests by private and public payers in each state and provide solutions to overcome reimbursement barriers.

Florida - Updates on Targeted Therapy

Louisiana - Lung Biomarker Testing Today & Tomorrow

Virginia - Genomic Testing at the Time of Resistance

South Carolina - What's Next in South Carolina

Arkansas - ACS CAN - Advocacy

Tennessee- Navigating Insurance Complexities

Florida - Biomarker-Driven Precision Medicine: Opportunities & Challenges

Virginia - ASCO Updates